Shares of BioAge (NASDAQ:BIOA) cratered 70% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its ... Updates stock move.) More on BioAge Labs, Inc.

Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug cibotercept in patients with pulmonary arterial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novo Nordisk’s phase III REDEFINE 1 study evaluating its next-gen subcutaneous ... performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five ...

In November, the FDA granted Orphan Drug Designation to neflamapimod for frontotemporal dementia (FTD). Price Action: CRVO stock is down 78.2% at $2.24 last check Tuesday.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Now is the time to recognize how an abundance of material things is taking up space in your home (and your brain). Put on ...

In this multicentre retrospective study, we collected data for patients with lung cancer who had a biopsy and multigene next-generation sequencing done at 16 hospitals in China (with no restrictions ...

BeiGene ($BGNE) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved ...

Learn how to invest in stocks, including how to select a brokerage account and research stock market investments. Many, or all, of the products featured on this page are from our advertising ...

Foxtel sold for $3.4 billion to a British streaming outfit, while the ASX 200 gained 1.7 per cent, recouping much of last week's losses. Here's how the day's trade unfolded, with insights from our ...